Description
Anti-Granulysin Antibody, Non-Fucosylated (BioBet-937ZP) is a humanized monoclonal IgG antibody against Granulysin. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
tevens-Johnson Syndrome
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Granulysin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GNLY
Full Name
granulysin
Background
The product of this gene is a member of the saposin-like protein (SAPLIP) family and is located in the cytotoxic granules of T cells, which are released upon antigen stimulation. This protein is present in cytotoxic granules of cytotoxic T lymphocytes and natural killer cells, and it has antimicrobial activity against M. tuberculosis and other organisms. Alternatively spliced transcript variants encoding different isoforms have been identified.
Alternative Names
GNLY; granulysin; 519; LAG2; NKG5; LAG-2; D2S69E; TLA519; lymphokine LAG-2; lymphocyte-activation gene 2; T-cell activation protein 519; T-lymphocyte activation gene 519
Gene ID
10578
UniProt ID
Q9UK05
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with GNLY include Erythema Multiforme and Kyphoscoliotic Heart Disease.
Related Pathways
Its related pathways are Allograft rejection and Innate Immune System.
Function
Antibacterial protein that kills pathogens in cells. It is effective against many microorganisms, including Gram-positive and Gram-negative bacteria, fungi and parasites. Kill Mycobacterium tuberculosis.
Post-translational modifications
A 9 kDa form is produced by proteolytic processing of a 15 kDa protein.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-937ZP
Description
This is an anti-granulysin antibody capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. It can be used for treating or preventing an unwanted immune response disorders.
Antibody Indication
tevens-Johnson Syndrome
